Hardman & Co Research: Shield Therapeutics ...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability 13-Jan-2023 / 07:15 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Positioned for growth and profitability Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, with the aim of generating prescription (Rx) growth and sales traction. Positive momentum in 2H’22 should be accelerated substantially in 2023, with Viatris as its new commercial partner, and increased resources from a capital increase. In the event that the US goals are achieved, there would be considerable upside potential to the valuation. Please click on the link below for the full report: https://hardmanandco.com/research/corporate-research/positioned-for-growth-and-profitability/ If you are interested in meeting the company, you can register your interest by clicking on the above link. To contact us: Hardman & Co 1 Frederick’s Place London EC2R 8AE www.hardmanandco.com Follow us on Twitter @HardmanandCo Contact: Martin Hall [phone] [e-mail]   Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report. Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

1534157 13-Jan-2023